ArticlePloS one2011
Antibiofilm activity of an exopolysaccharide from marine bacterium Vibrio sp. QY101.
Article in PloS one, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 58 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
58 citing papers in PubMed, 159 citations in OpenAlex.
- Lactic Acid Bacteria as Natural Antimicrobials: Biofilm Control in Food and Food Industry.Antibiotics (Basel, Switzerland) · 2026Review
- Antibiofilm compounds from Streptomyces Labedae 20PM improves survival of and prophylactic effect of Nile tilapia (Oreochromis niloticus) challenged with Aeromonas hydrophila.BMC research notes · 2026Article
- Comparative Optimization of Culture Media for Enhanced β-Glucan Production byFood science & nutrition · 2025Article
- Comprehensive evaluation of bioactive properties and metabolomic profiling of probiotic bacteria Lactococcus lactis (MKL8).Scientific reports · 2025Article
- Bio-informed synthesis of marine-sourced indole derivatives: suppressing gram-negative bacteria biofilm and virulence.BMC biology · 2025Article
- Burn Wound Healing Abilities of a Uronic Acid Containing Exopolysaccharide Produced by the Marine Bacterium Halomonas malpeensis YU-PRIM-29Applied biochemistry and biotechnology · 2024Article
- Anti-Biofilm Extracts and Molecules from the Marine Environment.Marine drugs · 2024Review
- Exploring the Exopolysaccharide Production Potential of Bacterial Strains Isolated from Tunisian Blue CrabMolecules (Basel, Switzerland) · 2024Article
- Bacterial adhesion inhibition by microalgal EPSs from Cylindrotheca closterium and Tetraselmis suecica biofilms.Applied microbiology and biotechnology · 2024Article
- A Poly-D-Mannose Synthesized by a One-Pot Method Exhibits Anti-Biofilm, Antioxidant, and Anti-Inflammatory Properties In Vitro.Antioxidants (Basel, Switzerland) · 2023Article
- Anti-Bacterial Adhesion on Abiotic and Biotic Surfaces of the Exopolysaccharide from the Marine Bacillus licheniformis B3-15.Marine drugs · 2023Article
- Evaluation of Bioactive Attributes and Emulsification Potential of Exopolysaccharide Produced by a Brown-rot Fungus Fomitopsis meliae AGDP-2.Applied biochemistry and biotechnology · 2023Article
- Antibiofilm activity from endophyte bacteria, Vibrio cholerae strains, and actinomycetes isolates in liquid and solid culture.BMC microbiology · 2023Article
- Anti-Biofilm Activity of a Hyaluronan-like Exopolysaccharide from the MarineMarine drugs · 2022Article
- Antibiofilm properties of bioactive compounds from Actinomycetes against foodborne and fish pathogens.Scientific reports · 2022Article
- Exopolysaccharides from Marine Microbes: Source, Structure and Application.Marine drugs · 2022Review
- An Overview of Biofilm Formation-Combating Strategies and Mechanisms of Action of Antibiofilm Agents.Life (Basel, Switzerland) · 2022Review
- Characteristics and Biological Activity of Exopolysaccharide Produced byMicroorganisms · 2022Article
- Non-serogroup O1/O139 agglutinable Vibrio cholerae: a phylogenetically and genealogically neglected yet emerging potential pathogen of clinical relevance.Archives of microbiology · 2022Review
- Fucose-containing bacterial exopolysaccharides: Sources, biological activities, and food applications.Food chemistry: X · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Bacterial exopolysaccharides have always been suggested to play crucial roles in the bacterial initial adhesion and the development of complex architecture in the later stages of bacterial biofilm formation. However, Escherichia coli group II capsular polysaccharide was characterized to exert broad-spectrum biofilm inhibition activity. In this study, we firstly reported that a bacterial exopolysaccharide (A101) not only inhibits biofilm formation of many bacteria but also disrupts established biofilm of some strains. A101 with an average molecular weight of up to 546 KDa, was isolated and purified from the culture supernatant of the marine bacterium Vibrio sp. QY101 by ethanol precipitation, iron-exchange chromatography and gel filtration chromatography. High performance liquid chromatography traces of the hydrolyzed polysaccharides showed that A101 is primarily consisted of galacturonic acid, glucuronic acid, rhamnose and glucosamine. A101 was demonstrated to inhibit biofilm formation by a wide range of Gram-negative and Gram-positive bacteria without antibacterial activity. Furthermore, A101 displayed a significant disruption on the established biofilm produced by Pseudomonas aeruginosa, but not by Staphylococcus aureus. Importantly, A101 increased the aminoglycosides antibiotics' capability of killing P. aeruginosa biofilm. Cell primary attachment to surfaces and intercellular aggregates assays suggested that A101 inhibited cell aggregates of both P. aeruginosa and S. aureus, while the cell-surface interactions inhibition only occurred in S. aureus, and the pre-formed cell aggregates dispersion induced by A101 only occurred in P. aeruginosa. Taken together, these data identify the antibiofilm activity of A101, which may make it potential in the design of new therapeutic strategies for bacterial biofilm-associated infections and limiting biofilm formation on medical indwelling devices. The found of A101 antibiofilm activity may also promote a new recognition about the functions of bacterial exopolysaccharides.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.